Stem Cell Boost vs Supportive Care for Prolonged Cytopenias After CAR-T | Cindy Varga, MD

Stem Cell Boost vs Supportive Care for Prolonged Cytopenias After CAR-T | Cindy Varga, MD
Cilta-Cel Outside Specs: How Safe & Effective Is It in Relapsed Myeloma? | Azra Borogovac, MD
Treating Plasma Cell Leukemia: New Insights on Bispecific Antibodies | Mahmoud Gaballa, MD
Myeloma Maintenance: Daratumumab as an Alternative to Lenalidomide | Sridevi Rajeeve, MD
Bispecific Therapies in Myeloma: Preferences & Priorities | Thomas LeBlanc, MD
Fitness analysis of Isa-VRD transplant ineligible myeloma patients | Enrique Ocio, MD
Circulating tumor cells (CTCs) improve myeloma risk stratification | Mattia D'Agostino, MD
REVIVE Trial : Dara + Bispecific in High-Risk Smoldering Myeloma | Ola Landgren, MD, PhD
New Talquetamab Combos Show Promise for Longer-Lasting Myeloma Control | Jeffrey Matous, MD
Choosing the Best Induction Therapy for Fit Patients With Myeloma | Jonathan Kaufman, MD
Can Patient Questionnaires Reduce the Need for Eye Exams with Belantamab?| Rakesh Popat, PhD
Teclistamab & CMV: Risks and Clinical Outcomes Explained | Samer Al Hadidi, MD
Can Sonrotoclax Improve Outcomes in t(11;14) Relapsed Myeloma? | Rakesh Popat, PhD
Insights from a community oncologist on myeloma bispecific antibodies | Ira Zackon, MD
Preventing Myeloma Relapse Using a Response Adaptive Dosing Approach | Erin Meermeier, PhD
Belamaf + VRd for Newly Diagnosed Transplant-Ineligible Myeloma Patients | Saad Usmani, MD
Monoclonal Gammopathy of Renal Significance: Hematologic Perspective | Heather Landau, MD
First U.S. CAR-T Trial for AL Amyloidosis Shows Promise | Heather Landau, MD
Real-Time Symptom Tracking for Myeloma Patients | James Berenson, MD
Long-Term Success with Talquetamab Combo Therapy | Hang Quach, MD
Dual Antibody Combo (Tec + Tal) Shows Hope for Hard-to-Treat Myeloma | Saad Usmani, MD
Talquetamab Outcomes in R/R Myeloma with Extramedullary Disease | Aimaz Afrough, MD
Nirogacestat Enhances BCMA Expression & Improves Blenrep Response? | Malin Hultcrantz, MD, PhD